We are a leading technology platform that unlocks unlimited possibilities for the future of medicine through our intelligent modular design and tailored hyper targeting.
Location: Norway, Oslo
Employees: 51-200
Founded date: 2007
Investors 4
| Date | Name | Website |
| - | TD Veen | tdveen.no |
| - | Kvantia | kvantia.no |
| - | p53 | p53.no |
| - | Sarsia | sarsia.com |
Mentions in press and media 3
| Date | Title | Description |
| 11.02.2022 | Nykode Therapeutics announces completion of patient enrollment in its Phase 2 trial of VB10.16 in combination with atezolizumab for the treatment of advanced cervical cancer | Nykode Therapeutics has reached the enrollment target of 50 patients in its VB C-02 trial for the treatment of advanced cervical cancer Interim efficacy and safety data expected in 1H 2022 OSLO, Norway, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Nyk... |
| 28.12.2021 | Nykode Therapeutics announces first subject dosed with its T cell focused next-generation SARS-CoV-2 vaccine candidate | First subject dosed with Nykode Therapeutics’ T cell focused SARS-CoV-2 vaccine candidate. This is part of the ongoing phase 1/2 two-arm clinical trial VB-D-01 designed to specifically address emerging variants of concern, including Omicron... |
| 15.12.2021 | New chairman at Nykode Therapeutics as the Company enters a new stage of internationalization | o Martin Nicklasson proposed as new chairman at Nykode Therapeutics as the Company enters a new stage of internationalization o Anders Tuv to continue as an ordinary board member Oslo, Norway, December 15, 2021 - Nykode Therapeutics (former... |